Therapy-induced antitumor vaccination in neuroblastomas by the combined targeting of IL-2 and TNFalpha. - Wikidata - wikimedia - TriplyDB

Therapy-induced antitumor vaccination in neuroblastomas by the combined targeting of IL-2 and TNFalpha.

Therapy-induced antitumor vaccination in neuroblastomas by the combined targeting of IL-2 and TNFalpha.

http://www.wikidata.org/entity/Q39781613

about

Optimal MHC-II-restricted tumor antigen presentation to CD4+ T helper cells: the key issue for development of anti-tumor vaccines Immunocytokines and bispecific antibodies: two complementary strategies for the selective activation of immune cells at the tumor site Prognostic value of the preoperative immunological profile in patients with glioblastoma.Combination of temozolomide with immunocytokine F16-IL2 for the treatment of glioblastoma.The antibody-based targeted delivery of TNF in combination with doxorubicin eradicates sarcomas in mice and confers protective immunity.Schedule-dependent therapeutic efficacy of L19mTNF-α and melphalan combined with gemcitabine Immunocytokines: a novel class of products for the treatment of chronic inflammation and autoimmune conditions.Immunocytokines for cancer treatment: past, present and future.Oncolytic Adenoviruses Armed with Tumor Necrosis Factor Alpha and Interleukin-2 Enable Successful Adoptive Cell Therapy.Current and future management strategies for relapsed or progressive hepatoblastoma.Adequate antigen availability: a key issue for novel approaches to tumor vaccination and tumor immunotherapy.Immunocytokines: a review of molecules in clinical development for cancer therapy.Boosting the MHC Class II-Restricted Tumor Antigen Presentation to CD4+ T Helper Cells: A Critical Issue for Triggering Protective Immunity and Re-Orienting the Tumor Microenvironment Toward an Anti-Tumor State.The therapeutic T-cell response induced by tumor delivery of TNF and melphalan is dependent on early triggering of natural killer and dendritic cells.Antibody-based targeting of interferon-alpha to the tumor neovasculature: a critical evaluation.Antibody-based delivery of tumor necrosis factor (L19-TNFα) and interleukin-2 (L19-IL2) to tumor-associated blood vessels has potent immunological and anticancer activity in the syngeneic J558L BALB/c myeloma model.Antibody-cytokine fusion proteins for cancer immunotherapy: an update on recent developments.Strategy to targeting the immune resistance and novel therapy in colorectal cancer.Emerging classes of armed antibody therapeutics against cancer

P2860

Q27030560-131925B0-8DB7-4EA9-89BE-E365F0217C5C Q28066935-C4FC13BA-5CD7-4438-A31F-DE2371B0CF5F Q33887213-7AA0E53A-E2C2-408F-B906-AA5A6D5EACD9 Q34253705-C45018BF-49FD-4AFC-944B-98FBB029E79D Q37185752-A196C211-1B96-4D20-A131-29EEA9DA90EB Q37236248-49F81FB8-F68B-47A6-8A73-0553603BF1D2 Q37485709-1A3439B8-8370-4E16-BE8E-6C3A70CB58D8 Q37560208-344E787F-1824-4E73-82CC-2650BCCC8276 Q37718529-B07D383F-3064-4ECC-B730-1A18DD2FE4CF Q38019027-BF7681A7-7259-44DF-999E-9BA2463A97F4 Q38066025-89FFD60E-2FF1-4509-A7B6-72166DE4915A Q38132742-0439B28B-B0C7-45E5-A704-C99A5814169F Q38193821-C6826915-C0B7-454A-824E-55AB4948ACB3 Q38716421-53B015EE-31DD-4AA5-8A56-CA18FC794982 Q39609067-11F04004-CDA2-4CDE-B61E-3380FBE45F7B Q50073502-2E9803D9-2B26-4B25-8F8E-AC8C9F993026 Q51786117-177D3031-8EF9-4044-9918-9DF2FA9AB8E6 Q52320729-0182592B-DCC8-48E3-9CF2-80A26872245F Q57911948-DA91BCD7-D067-47F5-949A-6B609CC5CE24

P2860

Therapy-induced antitumor vaccination in neuroblastomas by the combined targeting of IL-2 and TNFalpha.

http://www.wikidata.org/entity/Q39781613

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

2010年论文

@zh

2010年论文

@zh-cn

name

Therapy-induced antitumor vacc ...... argeting of IL-2 and TNFalpha.

@en

Therapy-induced antitumor vacc ...... argeting of IL-2 and TNFalpha.

@nl

type

label

Therapy-induced antitumor vacc ...... argeting of IL-2 and TNFalpha.

@en

Therapy-induced antitumor vacc ...... argeting of IL-2 and TNFalpha.

@nl

prefLabel

Therapy-induced antitumor vacc ...... argeting of IL-2 and TNFalpha.

@en

Therapy-induced antitumor vacc ...... argeting of IL-2 and TNFalpha.

@nl

P1433

Q39781613-FFBAE593-529C-43B5-BA8D-76B297D6612E

P1476

Q39781613-C9C017C6-F4CD-4DDF-8356-8785F178CD88

P2093

Q39781613-03579C1D-FF26-47AD-B8F4-B2F92D0862C1

Q39781613-222474FE-FD66-4526-AE38-9A20D25E5D6F

Q39781613-2399ADFF-879B-4EA2-B2FF-DDCFA6091355

Q39781613-41D459FE-F8F4-427D-A45C-4E0114DF948A

Q39781613-5296B7A5-3639-4DF6-B12B-B343189FF33D

Q39781613-55BF5230-9EA5-41F5-B4F9-FA4774221CFB

Q39781613-F0E47765-1683-40EB-B316-86E73E0E7D12

P2860

Q39781613-00BD614D-C5A2-4D97-BBA5-349625E2984A

Q39781613-0D061751-6CC9-4D92-9838-98C565CC1AB5

Q39781613-261A8635-D59D-4FFC-9360-79A930AC1AE8

Q39781613-332DB970-F682-48B3-A8B0-0317C42104FB

Q39781613-44833218-2BD9-4F2D-A059-2A2BD0B73259

Q39781613-44EDDB48-5616-4F8A-9DFC-45B6A0A0E34F

Q39781613-5F4FFA55-D02E-4C97-B619-A8BA519579E0

Q39781613-604ED38E-3905-4458-A469-AAA038F226AB

Q39781613-6062FF48-381A-4EB2-97E2-18D413084757

Q39781613-6A3BB306-128C-49BA-9222-2CA324004E95

P304

Q39781613-3542DB65-418F-46E3-A0DC-F7FD3612C8D1

P31

Q39781613-C49A2C91-82DD-4882-A2F1-154F4C34764E

P356

Q39781613-C96D03DE-2A3C-48B2-92A0-06707B9C796F

P433

Q39781613-5F9758CA-8029-4EDD-85F4-BA63305A012A

P478

Q39781613-6FE1FA07-A5D8-4890-AD07-98114E5D3351

P577

Q39781613-5E567A37-921A-4581-BE7D-98D25B8EA167

P5875

Q39781613-203AA12E-1CA4-4F44-8D62-EA2D335A4DE7

P698

Q39781613-64C9F7E6-1A6A-401A-9ECD-F46FD175B620

P356

P1433

International Journal of Cancer

P1476

Therapy-induced antitumor vacc ...... argeting of IL-2 and TNFalpha.

@en

P2093

Barbara Carnemolla

http://www.w3.org/2001/XMLSchema#string

Debora Soncini

http://www.w3.org/2001/XMLSchema#string

Enrica Balza

http://www.w3.org/2001/XMLSchema#string

Laura Borsi

http://www.w3.org/2001/XMLSchema#string

Lorenzo Mortara

http://www.w3.org/2001/XMLSchema#string

Patrizia Castellani

http://www.w3.org/2001/XMLSchema#string

Roberto S Accolla

http://www.w3.org/2001/XMLSchema#string

P2860

The tumor-associated antigen PRAME is universally expressed in high-stage neuroblastoma and associated with poor outcome

Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses

Induction chemotherapy in metastatic neuroblastoma--does dose influence response? A critical review of published data standards, options and recommendations (SOR) project of the National Federation of French Cancer Centres (FNCLCC).

Tumor necrosis factor-mediated interactions between inflammatory response and tumor vascular bed.

Immunological gene therapy with ex vivo gene-modified tumor cells: a critique and a reappraisal.

Progress in human tumour immunology and immunotherapy.

Differentiation between high- and low-grade astrocytoma using a human recombinant antibody to the extra domain-B of fibronectin.

Reduction of interstitial fluid pressure after TNF-alpha treatment of three human melanoma xenografts.

Dendritic cell loss from nonlymphoid tissues after systemic administration of lipopolysaccharide, tumor necrosis factor, and interleukin 1

The central role of CD4(+) T cells in the antitumor immune response.

P304

101-110

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/IJC.25018

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

127

http://www.w3.org/2001/XMLSchema#string

P577

2010-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

229683254

http://www.w3.org/2001/XMLSchema#string

P698

19877124

http://www.w3.org/2001/XMLSchema#string